Abstract 14356: Flexibility and Contact Force: Improvements of the Next Generation Irrigated Gold-Tip Ablation Catheter for Remote Magnetic Navigation
Introduction: Remote magnetic navigation (RMN) has been proven safe and effective in ablation of arrhythmias. While for manual ablation new irrigation technologies are established in clinical practice , basic design of RMN catheters remained unchanged after initial improvements. Furthermore, distribution and strength of magnets in so far available products seem to be arbitrary and are unsatisfying in terms of flexibility and contact force (CF). For the development of a novel RMN catheter incorporating most recent irrigation technology, all aspects for a new mechanical catheter design were investigated with special focus on CF and flexibility.
Hypothesis: Improvements in flexibility and contact force can be achieved by a newly designed magnetic ablation catheter.
Methods: 13 different prototypes with various combinations of magnetic volume, magnet position and shaft design all equipped with an irrigated gold-tip were compared to 2 commercially available catheters in an experimental set-up (at 37°C). For CF testing all catheters were inserted in an 8.5 Fr, 65 cm standard sheath. The sheath was centered within a highly sensitive CF sensing instrument in a magnetic lab and maneuvered in parallel and perpendicular orientation by a motor-drive and a magnetic field of 0.1 Tesla. Three CF measurements were recorded and averaged for each position. Flexibility was tested by advancing all catheters out of the sheath to a defined distance, arranging the magnetic field in a 180° orientation and measuring the distance between sheath and tip electrode.
Results: The data for a selected prototype found to be most advantageous compared to two commercial versions are detailed in table 1.
Conclusions: CF and flexibility have been improved compared to commercially available RMN catheters. These findings led to the design of a RMN catheter also integrating most recent irrigation technology. Further studies are required to determine the clinical impact of these advancements.
Author Disclosures: G. Noelker: Honoraria; Modest; Biotronik. S. Molatta: None. D. Horstkotte: None. K. Gutleben: Other; Modest; Travel reimbursement by Biotronik.
- © 2016 by American Heart Association, Inc.